Ipswich Investment Management Co. Inc. Decreases Position in Eli Lilly And Co (LLY)

Share on StockTwits

Ipswich Investment Management Co. Inc. trimmed its holdings in Eli Lilly And Co (NYSE:LLY) by 13.7% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,357 shares of the company’s stock after selling 1,325 shares during the quarter. Ipswich Investment Management Co. Inc.’s holdings in Eli Lilly And Co were worth $1,084,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of the stock. Trust Department MB Financial Bank N A boosted its holdings in shares of Eli Lilly And Co by 54.7% during the 1st quarter. Trust Department MB Financial Bank N A now owns 232 shares of the company’s stock valued at $30,000 after acquiring an additional 82 shares during the last quarter. Captrust Financial Advisors boosted its holdings in shares of Eli Lilly And Co by 0.4% during the 4th quarter. Captrust Financial Advisors now owns 21,627 shares of the company’s stock valued at $2,503,000 after acquiring an additional 87 shares during the last quarter. Bronfman E.L. Rothschild L.P. boosted its holdings in shares of Eli Lilly And Co by 1.6% during the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 5,543 shares of the company’s stock valued at $641,000 after acquiring an additional 87 shares during the last quarter. First Personal Financial Services boosted its holdings in shares of Eli Lilly And Co by 2.3% during the 4th quarter. First Personal Financial Services now owns 3,931 shares of the company’s stock valued at $455,000 after acquiring an additional 89 shares during the last quarter. Finally, Carroll Financial Associates Inc. boosted its holdings in shares of Eli Lilly And Co by 1.3% during the 4th quarter. Carroll Financial Associates Inc. now owns 7,029 shares of the company’s stock valued at $810,000 after acquiring an additional 91 shares during the last quarter. Institutional investors own 79.58% of the company’s stock.

In other news, insider Donald A. Zakrowski sold 1,000 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $127.01, for a total value of $127,010.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Aarti S. Shah sold 1,800 shares of the stock in a transaction that occurred on Friday, April 5th. The stock was sold at an average price of $125.85, for a total transaction of $226,530.00. Following the completion of the transaction, the senior vice president now owns 18,425 shares in the company, valued at approximately $2,318,786.25. The disclosure for this sale can be found here. Insiders sold a total of 989,224 shares of company stock worth $123,587,253 in the last quarter. Company insiders own 0.11% of the company’s stock.

A number of analysts have recently issued reports on the stock. Zacks Investment Research raised shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $142.00 price target on the stock in a report on Wednesday, April 10th. Barclays reaffirmed a “buy” rating and set a $140.00 price target on shares of Eli Lilly And Co in a report on Sunday. Bank of America set a $129.00 price target on shares of Eli Lilly And Co and gave the company a “hold” rating in a report on Thursday, March 21st. Citigroup set a $124.00 price target on shares of Eli Lilly And Co and gave the company a “hold” rating in a report on Tuesday, February 26th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating on shares of Eli Lilly And Co in a report on Monday, February 4th. Ten research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $118.02.

Shares of NYSE:LLY opened at $124.08 on Tuesday. Eli Lilly And Co has a twelve month low of $77.09 and a twelve month high of $132.13. The company has a current ratio of 1.73, a quick ratio of 1.38 and a debt-to-equity ratio of 1.07. The company has a market capitalization of $127.47 billion, a PE ratio of 22.36, a price-to-earnings-growth ratio of 2.33 and a beta of 0.33.

Eli Lilly And Co (NYSE:LLY) last issued its quarterly earnings data on Wednesday, February 6th. The company reported $1.33 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.36 by ($0.03). Eli Lilly And Co had a return on equity of 44.66% and a net margin of 13.16%. The business had revenue of $6.44 billion during the quarter, compared to the consensus estimate of $6.28 billion. During the same quarter last year, the company earned $1.14 EPS. Eli Lilly And Co’s revenue for the quarter was up 4.5% on a year-over-year basis. As a group, analysts expect that Eli Lilly And Co will post 5.66 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by Macon Daily and is the sole property of of Macon Daily. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://macondaily.com/2019/04/16/ipswich-investment-management-co-inc-decreases-position-in-eli-lilly-and-co-lly.html.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

See Also: What is the price-to-earnings growth (PEG) ratio?

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.